Almirall SA 2009 AR2
The report highlights Almirall's solid financial and operational performance in 2009, with net sales increasing by 2.5% to €925.5 million, driven by international sales. The company achieved key milestones, including the launch of new products like Tesavel, Efficib, and Astucor, and signed major corporate development agreements such as the pan-European licensing of linaclotide. Almirall also made significant progress in its R&D pipeline, particularly in the respiratory and dermatology fields, allocating approximately 13% of net sales to R&D. Additionally, the company reinforced its social commitment by recycling 198 tonnes of paper and cardboard and maintaining its OHSAS 18001 and ISO 14001 certifications.
Company: Almirall SA
Sector: Manufacturing
Country: Spain
Year: 2009
Type: AR2
Pages: 113
Back to company
Almirall SA
Annual Report
The report highlights Almirall's solid financial and operational performance in 2009, with net sales increasing by 2.5% to €925.5 million, driven by international sales. The company achieved key milestones, including the launch of new products like Tesavel, Efficib, and Astucor, and signed major corporate development agreements such as the pan-European licensing of linaclotide. Almirall also made significant progress in its R&D pipeline, particularly in the respiratory and dermatology fields, allocating approximately 13% of net sales to R&D. Additionally, the company reinforced its social commitment by recycling 198 tonnes of paper and cardboard and maintaining its OHSAS 18001 and ISO 14001 certifications.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2009
Reporting Period
Jan 1, 2009 - Dec 31, 2009
Fiscal Year
2009
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees